Sort   by:  
 Page size 
MetabolomicsMapping human microbiome drug metabolism by gut bacteria and their genes

Individuals vary widely in their drug responses, which can be dangerous and expensive due to treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain largely unknown. We measured the ability of 76 diverse hum...

2019-07-10 | MTBLS896 | MetaboLights
MetabolomicsProtective Effects of Cordycepin against Oxaliplatin-Associated Drug-Induced Fatty Liver Disease and Preliminary Mechanistic Insights

Oxaliplatin (OXA) is a chemotherapeutic agent used to treat multiple malignancies. Although it predominantly causes hepatic sinusoidal obstruction syndrome, it also induces drug-induced fatty liver disease (DIFLD) via lipid metabolic dysregulation and oxidative stress, which persists post-cessati...

2025-09-04 | MTBLS12938 | MetaboLights
MetabolomicsConsistency across multi-omics layers in a drug-perturbed gut microbial community
Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the comm...
2022-12-08 | MTBLS3129 | MetaboLights
MetabolomicsAdjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a Phase IIA open-label pilot clinical trial

Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) aim to limit tissue damage, shorten treatment, and improve outcomes by modulating immune responses. We evaluated the safety and potential efficacy of adjunctive ibuprofen an inexpens...

2026-05-28 | MTBLS13376 | MetaboLights
MetabolomicsRabbit plasma metabolomic analysis of Nitroproston: a multi target natural prostaglandin based-drug (Untargeted study)
INTRODUCTION: Nitroproston® is a novel multi-target drug bearing natural prostaglandin E2 (PGE2) and nitric oxide (NO)-donating fragments for treatment of inflammatory and obstructive diseases (i.e. asthma and obstructive bronchitis). OBJECTIVES: To investigate the effects of Nitroproston® adm...
2019-08-27 | MTBLS727 | MetaboLights
Metabolomics1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
1H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1]6+ as potential anticancer drug. Human ovarian cancer cell...
2015-01-16 | MTBLS156 | MetaboLights
MetabolomicsCalenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects via the IRS1/PI3K/AKT signaling pathway in a type 2 diabetes model Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects via the IRS1/PI3K/AKT signaling pathway in cell, organ-on-a-chip, and mouse models of type 2 diabetes.

Glibenclamide (GLIB), a type 2 diabetes therapy, has long-term safety concerns. Probiotic–drug coadministration, an emerging adjunctive approach for metabolic diseases, improves therapeutic outcomes and side effects. Here, Bifidobacterium animalis B960 was selected from 71 probiotic strains by HP...

2025-07-08 | MTBLS12697 | MetaboLights
MetabolomicsUntargeted metabolomics of long-term drug intervention under standard diet in mice associated with lifespan

This study investigates urinary metabolic differences in young mice, aged mice, and aged mice supplemented with long-term drug intervention under standard diet. Untargeted metabolomics was performed using UHPLC-MS/MS in both positive (POS) and negative (NEG) ionization modes. The dataset provides...

2026-05-07 | MTBLS12889 | MetaboLights
MetabolomicsMetabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery
Psoriasis is a chronic skin disease that affects multiple systems and can be influenced by immunological, environmental, and genetic factors. The discovery of plasma biomarkers of psoriasis and the regulation of metabolic pathways helps us understand psoriasis and may assist clinicians in the diagno...
2024-09-26 | MTBLS5185 | MetaboLights
MetabolomicsMirabegron displays anticancer effects by globally browning adipose tissues

Metabolic reprogramming in malignant cells is a hallmark of cancer that relies on augmented glycolytic metabolism to support their growth, invasion and metastasis. However, the impact of global adipose metabolism on tumor growth and the drug development by targeting adipose metabolism remain larg...

2023-11-08 | MTBLS8682 | MetaboLights
Sort   by:  
 Page size